DDR gene mutations associated with complete response to chemo in bladder cancer

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Nicholas M. Jaidar was named senior administrator for oncology at the Department of Oncology at the Johns Hopkins University School of Medicine and the Johns Hopkins Hospital.

June 27, 2025

Vol.51 No.25

Clinical Roundup

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

FDA has approved Zusduri as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Drugs & Targets

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Meitheal Pharmaceuticals Inc. on May 29 announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd., paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane, in the U.S.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Study uncovers source of genetic variation influencing childhood brain tumors

Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.

May 23, 2025

Vol.51 No.20

DDR gene mutations associated with complete response to chemo in bladder cancer

YOU MAY BE INTERESTED IN

Nicholas Jaidar named senior administrator for oncology at Johns Hopkins

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Study uncovers source of genetic variation influencing childhood brain tumors

Renew today!

Subscriber content

Never miss an issue!

Login